CD274 and hepatocellular carcinoma: In this research, HAIC plus PD-(L)1 inhibitors and anti-angiogenic agents in patients with antitumor treatment-naive infiltrative HCC yielded a median PFS of 7.5 months, an ORR of 70.4%, and durable responses (7.9 months).